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We analysed the expression of microsatellite instability, p53, p21, vascular endothelial growth factor and thymidylate synthase (TS) in
pretreatment biopsy specimens from 57 locally advanced rectal cancers. The aim of the study was to correlate the expression of
these markers with pathological response. Nineteen patients were treated with preoperative concomitant radiotherapy (RT) and
fluorouracil/oxaliplatin-based chemotherapy (RCT), while 38 had RT alone. Pathological complete remission (pCR) and microfoci
residual tumour (micR) occurred more frequently in patients treated with RCT (P¼0.002) and in N0 tumours (P¼0.004). Among
patients treated with RCT, high TS levels were associated with a higher response rate (pCRþmicR; P¼0.015). No such correlation
was found in the RT group. The other molecular factors were of no predictive value. Multivariate analysis confirmed a significant
interaction between nodal status and the probability of achieving a pathological response (P¼0.023) and between TS expression and
treatment, indicating that a high TS level is predictive of a higher pathological response in the RCT subset (P¼0.007). This study
shows that lymph node status is the most important predictive factor of tumour response to preoperative treatment. Thymidylate
synthase expression assessed immunohistochemically from pretreatment tumour biopsies may be a useful predictive marker of rectal
tumour response to preoperative RCT.
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Preoperative radiation therapy alone (RT) or combined with
chemotherapy (RCT) and improvements in surgical techniques,
particularly the standardisation of total mesorectal excision
(TME), have led to improved outcomes in the management of
locally advanced rectal cancer in recent years (Swedish Rectal
Cancer Trial, 1997; Sauer et al, 2004). With this approach,
pathologic complete response (pCR), which is an important
clinical predictor for both local control and disease-free survival,
is achieved in 7–31% of patients (Ruo et al, 2002). In addition,
obtaining a complete or near-complete pathologic response before
surgery may increase the number of sphincter-sparing procedures
(Ruo et al, 2002). The ability to predict tumour response before
treatment may significantly impact the selection of patients for
preoperative combined-modality therapy as well as potentially
modify postoperative treatment plans.
Thymidylate synthase (TS), the target enzyme of the antimeta-
bolite 5-FU, has been shown to be an independent prognostic
marker of 5-FU chemotherapy in gastrointestinal tumours. Several
preclinical and clinical studies have demonstrated that high TS
levels correlate with 5-FU resistance in various malignancies
(Leichman et al, 1997; Aschele et al, 1999). However, most of these
studies dealt with outcome prediction for postoperative
chemotherapy or treatment of metastatic disease rather than
preoperative treatment. Therefore, the potential of TS expression
levels to predict response to preoperative combined-modality
therapy remains unsettled.
Little is known about other potential biological markers, such as
p53, p21 and radio- and chemosensitivity of rectal cancer cells.
Vascular endothelial growth factor (VEGF) is a potent mediator of
tumour angiogenesis and has currently been assessed as a response
predictor in rectal cancer. The results of a recently published study
show that VEGF assessed immunohistochemically from pretreat-
ment tumour biopsies may be a useful marker for rectal tumour
response to preoperative RT (Zlobec et al, 2005a).
The aim of the present study was to test the predictive value of a
number of tissue biomarkers, including TS, VEGF, p53, p21, MLH1
and MSH2 with regard to preoperative RT alone or RCT in rectal
cancer.
MATERIALS AND METHODS
A total of 57 patients with stage II and III rectal cancer
consecutively treated at our Institution were included in this
study, provided that adequate archive tumour tissue from
pretreatment biopsy was available for biological studies. Disease
staging was by computed tomography scan in all patients.
Endorectal ultrasonography was performed in 17 patients.
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using high energy Linac (total dose 40Gy specified to the isocentre,
250cGyday
 1, four fractions per week), delivered in 16 fractions,
to include the true pelvis (rectal volume, perirectal, presacral and
iliac nodes) with the three-field technique and shaped portals.
Another 19 patients were treated within a phase II trial with
preoperative radiation (total dose 45Gy to the isocentre,
180cGyday
 1, with the three-field technique and shaped portals
to cover the rectal volume and the perirectal, presacral and the
internal iliac lymph nodes) and concurrent continuous infusion
5-FU at a daily dose of 200mgm
 2 and weekly oxaliplatin
60mgm
 2 for 5 weeks. The trial was approved by the Ethics
Committee of our Institution. Informed consent was obtained from
all patients. All the patients underwent surgery regardless of
radiological response, which was not routinely performed.
Standard surgery, including total mesorectal excision, was
performed in all patients after an interval of approximately 6
weeks after completion of treatment. Further adjuvant treatment
after surgery was left to the discretion of the treating physician.
Only 18 of the 57 patients (32%) received in addition 5-FU-based
adjuvant chemotherapy.
Immunohistochemistry
Pretreatment tumour biopsies were collected from 57 patients. The
specimens containing tumour were routinely fixed in buffered
formalin and embedded in paraffin. Sections (4mm) were stained
with haematoxylin and eosin for histological diagnosis and with
the following primary antibodies: anti-HMSH2 (clone F11;
Oncogene Research Products, Cambridge, MA, USA; working
dilution 1/20); anti-HMLH1 (clone G168–728; Pharmingen, San
Diego, CA, USA; working dilution 1/100); anti-p53 (clone DO-7;
DakoCytomation, Glostrup, Denmark; working dilution 1/100);
anti-p21waf (clone DCS-60.2; Neomarkers, Runcorn, UK; working
dilution 1/20); anti-TS (clone TS 106; Chemicon; working dilution
1/50) and rabbit anti-VEGF (BioGenex, San Ramon, CA, USA;
working dilution 1/50). For antigen retrieval, sections were treated
with 10mM citrate at pH 6.0 in a 750W microwave oven for three
5-min cycles. The sections were immunostained with HRP Polymer
(Ultravision LP Large Volume Detection System; Lab Vision) in
accordance with the manufacturer’s specifications. Diaminobenzi-
dine was used for staining development and the sections were
counterstained with haematoxylin. Negative controls consisted of
substituting normal mouse serum for the primary antibodies.
Semiquantitative analysis Immunostaining for HMSH2 and
HMLH1 was estimated on a semiquantitative score according to
the number of positive tumour cells as follows: 0% (0), o10% (1),
10–50% (2), 51–80% (3) or 480% (4). The intensity of staining
was also evaluated as weak (1þ), moderate (2þ) or strong (3þ).
For each tumour case, the values for the two variables were
multiplied, resulting in a score ranging from 0 to 12. The 0–6
scores were considered as altered expression and 7–12, as
preserved expression. Vascular endothelial growth factor staining
was considered positive in the tumour cell cytoplasm; immuno-
reactivity was graded as follows: positive, more than 10% of
carcinoma cells stained, and negative less than 10% of carcinoma
cells stained. For the evaluation of p53 and p21waf expression,
immunostaining were classified into two groups, corresponding to
the percentage of nuclear staining: negative expression (less than
10% positive tumour cells) and positive expression (more than
10% positive tumour cells). Thymidylate synthase expression was
quantitated using a visual grading system based on the intensity of
staining and was classified into groups from 0 to 3, where 0 and 1
were defined as low intensity, and 2 and 3 were defined as high
intensity staining.
Assessment of immunoreactivity from pretreatment tumour
biopsies was performed independently by two observers
(PC and CB), blinded to postoperative tumour response. In case
of disagreement, the relevant biopsies were re-examined simulta-
neously by both pathologists until an agreement was reached.
Response classification
Tumour response was evaluated pathologically on postoperative
specimens. Pathological complete remission was defined as no
evidence of residual carcinoma or ypT0N0. Partial response was
characterised by the presence of residual carcinoma microfoci
(micR) typically measuring from 0.3 to 0.9cm in diameter. Non-
responsive tumours (NR) have large residual carcinoma. For the
correlation between biomarkers and response to treatment, we
separated the patients into two groups: responding (pCR, and
partial response characterised by the presence of micR;
pCRþmicR) vs NR (Zlobec et al, 2005b).
Statistics
Fisher’s exact test was used to compare the distribution of the
dichotomised molecular markers and tumours’ characteristics in
the two groups (responders and non-responders). Po0.05 was
considered statistically significant. To assess the presence of
a significant influence of treatment, tumour stage and molecular
markers on response, the multivariate logistic regression model
was applied, including in the model the appropriate interaction
terms between treatment and TS status. The SPSS Software
(version 8.0) was used in all analysis.
RESULTS
Patient and tumour characteristics are summarised in Table 1.
There were 32 men (56%) and 25 women (44%). Median age was
66 years (range 33–88). Thirty-eight patients (67%) were treated
with RT only and 19 (33%) with RCT. An anterior resection was
performed in 38 of 57 patients (67%). Only two patients treated
with RT alone had an incomplete resection (R1). Nodal involve-
ment was observed in 33 patients (58%). Eighteen percent of the
patients (6/33 patients) with N1–2 tumours received RCT and 82%
(27/33 patients) received RT alone.
Overall, pCR was observed in six patients (11%; 95% CI,
2.9–19.1%). In a further seven patients (12%; 95% CI, 3.6–20.4%),
only microscopic tumour foci were found. Pathologic tumour
response by treatment is shown in Table 2. Among patients treated
with RCT, pCR was observed in four patients (21%; 95% CI,
2.7–39.3%) and another five patients (26%; 95% CI, 6.3–45.7%)
had only micR (pCRþmicR¼47%). In the RT group, pCR was
observed in two patients (5%; 95% CI,  1.9–11.9%) and another
two patients (5%; 95% CI,  1.9–11.9%) had only micR (pCRþ
micR¼10%) (P¼0.002; Table 2).
Table 2 shows response rates according to various clinical and
biological parameters. Forty-seven percent of the patients (9/19
patients) with N0 tumours experienced an objective response. In
N1–2 tumours, only 9% of the patients (3/33 patients) responded
to treatment (P¼0.004; Table 2). In the present series, overall all
the other variables, including T status, TS, VEGF, p53, p21, MLH1
and MSH2 expression, failed to affect the probability of response
(Table 2).
Table 3 shows the subgroup exploratory analysis by treatment
according to TS status. Interestingly, among patients treated with
RCT, the percentage of pCRþmicR was significantly greater in
tumours with high TS expression levels than in those with low TS
levels (88 vs 12%; P¼0.015). In contrast, the response rate in RT
group was not affected by TS expression (13 vs 9%, respectively).
Subgroup analysis confirmed the lack of predictive value of p53,
p21, VEGF, MLH1 and MSH2.
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response, a regression logistic model was used, with the probability
of achieving a response as dependent variable and TS status, nodal
status, treatment and the interaction terms as covariates. Besides
nodal status (odds ratio (OR)¼8.0; 95% CI 1.34–47.8, P¼0.023),
only the interaction of TS and treatment was kept in the model as
independent predictive factors for response (OR¼30.6; 95% CI
2.5–371.7, P¼0.007). As a consequence of this interaction, the
increased activity seen in tumours expressing high TS levels in
patients treated with preoperative RCT was not seen in patients
treated with RT only (OR¼1.5; 95% CI 0.14–16.3).
DISCUSSION
Multidisciplinary treatment of rectal cancer has evolved over the
years from adjuvant chemoradiation to preoperative radiation and,
more recently, to preoperative combined chemoradiation, in view
of an improved toxicity and local control (Sauer et al, 2004).
Oxaliplatin added to FU was found to enhance the efficacy in
both metastatic and adjuvant colon cancer setting and may act as a
potent radiation sensitiser. For these reasons, this regimen is also
being used increasingly in preoperative treatment of rectal cancer.
Concomitant RT and oxaliplatin with either FU/LV or capecitabine
can achieve pCR rates in 15–28% in locally advanced rectal cancer
(Aschele et al, 2005; Chau et al, 2006). The results of the present
study show that, besides disease extent, the type of treatment is
the most important predictor of tumour response, with patients
treated with combined RCT having a higher probability of
achieving a pCR compared to those treated with RT alone
(P¼0.002). A pCR rate of 21% with an additional 26% micR rate
in the RCT group in this study is encouraging. A high response
rate is of clinical significance in rectal cancer because patients who
achieve a complete or near-complete pathologic response may
experience improved long-term local control and overall survival
(Ruo et al, 2002). Therefore, the identification of distinct clinical,
pathological and molecular parameters, with the ability to predict
Table 1 Baseline characteristics
Baseline characteristic Number of patients (N¼57) %
Age, years
Median 66
Range 33–88
Sex
Male 32 56
Female 25 44
Tumour stage
T1–2 12 21
T3–4 43 75
N0 19 33
N1–2 33 58
Preoperative treatment
RT 38 67
RCT 19 33
Surgery
Abdominoperineal resection 15 26
Sphincter-preserving surgery 38 67
TS
Low 22 39
High 32 56
P53
Negative 13 23
Positive 44 77
VEGF
Negative 21 37
Positive 31 54
P21
Negative 24 42
Positive 32 56
MLH1
Preserved 43 75
Altered 14 25
MSH2
Preserved 44 77
Altered 13 23
Abbreviations: RT¼radiotherapy; RCT¼radiochemotherapy; TS¼thymidilate
synthase; VEGF¼vascular endothelial growth factor.
Table 2 Response according to various clinical and pathological
parameters
Parameter Response % No response % P-value
Tumour stage 0.71
T1–2 2 17 10 83
T3–4 11 26 31 74
Nodal status 0.004
N0 9 47 10 53
N1–2 3 9 30 91
Treatment 0.002
RT 4 10 34 90
RCT 9 47 10 53
TS 0.20
Low 3 14 18 86
High 10 32 21 68
P53 0.71
Negative 2 15 11 85
Positive 11 26 31 74
VEGF 0.31
Negative 7 33 14 67
Positive 5 17 24 83
P21 0.74
Negative 4 18 18 82
Positive 8 25 24 75
MLH1 0.15
Preserved 12 29 29 71
Altered 1 7 13 93
MSH2 0.71
Preserved 11 26 31 74
Altered 2 15 11 85
Table 3 Response to preoperative treatment according to TS level
Treatment TS level Response No response P-value
CRT
High (n¼8) 7 (88%) 1 (12%) 0.015
Low (n¼10) 2 (20%) 8 (80%)
RT
High (n¼23) 3 (13%) 20 (87%) NS
Low (n¼11) 1 (9%) 10 (90%)
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therapeutic management of rectal cancer.
Thymidylate synthase plays an important role in pyrimidine
nucleotide synthesis and represents an important chemotherapeu-
tic target for 5-FU. Overall, the proportion of colorectal cancers
expressing high levels of TS is about 50% (range, 14–80%) in both
advanced and adjuvant settings (Edler et al, 2002; Johnston et al,
2003). In our study, the percentage of low and high TS expressors
was 39 and 56%, respectively.
Several studies have been published during the past few years
relating to the measurement of expression of TS to response to
fluoropyrimidines as well as to the overall outcome of patients with
colorectal carcinoma. A recent meta-analysis showed that color-
ectal cancers expressing TS at high levels seem to be associated
with a poorer prognosis compared with low TS-expressing
tumours, although in the adjuvant setting this seems to be the
case only for patients treated by surgery alone. In patients treated
with both surgery and adjuvant 5-FU, TS expression does not seem
to predict clinical outcome (Popat et al, 2004).
A direct correlation between TS expression and response to
5-FU has been reported both in vitro and in vivo. Preclinical
studies have demonstrated that an increase in TS expression is
associated with resistance to fluoropyrimidines (Johnston et al,
1992). In advanced colorectal cancer, patients with high levels of
TS are unlikely to respond to 5-FU, whereas patients with low
levels have higher than expected response rates (450%) (Aschele
et al, 1999; Cascinu et al, 1999).
To date, only a small number of studies have concentrated on
the role of TS and tumour response in rectal cancer patients,
especially 5-FU-based chemoradiotherapy. In rectal cancer, low TS
gene expression has been found to correlate significantly with
tumour response after neoadjuvant 5-FU-based CRT (Jakob et al,
2005). In contrast with these results, the present study indicates
that tumours responding to preoperative RCT most often express
high levels of TS in their pretreatment biopsies, whereas non-
responding tumours are generally poorly immunoreactive.
Several factors can account for the controversial results on the
predictive/prognostic role of TS expression. The first is related to
the different techniques used to assess TS expression. The
commonest technique used is IHC (Popat et al, 2004). Several
semiquantitative methods for dichotomising TS expression have
been used. The most common method relates TS expression to
chromagen intensity with either a 4- or 5-grade scale. Some studies
further subcategorised staining by a either focal or diffuse pattern.
In a recently published study, for example, a significant correlation
between protein expression and tumour response in rectal cancer
patients was seen only when both staining intensity and staining
pattern were considered, with a significant association between
high TS expression in tumour biopsies and non-response to
therapy (P¼0.04) (Jakob et al, 2005). In our study, we used a four
chromagen intensity grade, ranging from 0 to 3, where 0 and 1
were defined as low intensity, and 2 and 3 were defined as high
intensity staining, as reported previously (Allegra et al, 2002). The
existence of such a high variability supports the demand for
a more uniform evaluation of IHC expression.
Another reason for the contradictory results may be related to
the different FU schedule used. FU may act as two different drugs
according to the mode of administration. Bolus FU may exert its
major effect on RNA, whereas continuous infusion may have
a preferential effect on TS (Sobrero et al, 1997). Most published
studies of patients with advanced colorectal cancer indicate that
patients with high tumour levels of TS are unlikely to respond to
infusional treatment with 5FU (Leichman et al, 1997; Aschele et al,
1999). In contrast, in the present study, FU was administered as
continuous infusion at a daily dose of 200mgm
 2 and high TS
levels were found to be predictive of response to RCT.
There is some evidence that high TS protein expression may
predict high sensitivity to FU in the adjuvant setting. At least four
studies have suggested that patients whose primary tumours had
high TS expression may benefit from FU-based adjuvant
treatment, while those whose tumours had low expression do not
(Johnston et al, 1994; Yamachika et al, 1998; Takenoue et al, 2000;
Edler et al, 2002). In rectal cancer, adjuvant FU-based chemother-
apy demonstrated significant improvement in disease-free and
overall survival for rectal cancer patients with high TS levels
(Johnston et al, 1994). To our knowledge, this is the first study to
suggest that patients who have high TS-expressing rectal cancer
have a higher probability to respond to preoperative CRT.
It should also be noted that many more studies were conducted
regarding the prognostic value of TS expression in primary
colorectal cancer treated with postoperative chemotherapy and the
role of TS expression as a predictor of chemotherapeutic benefit in
metastatic disease rather than response prediction to preoperative
therapy. Importantly, TS expression measured in primary tumours
may not reflect TS levels in lymph node or other metastases
(Marsh et al, 2002).
Moreover, evidence has accumulated that oxaliplatin treatment
results in downregulation of TS expression, providing a possible
explanation, although still speculative, for the higher response rate
of the combination of oxaliplatin and FU, compared with
oxaliplatin alone, in FU-resistant patients (Yeh et al, 2004). In
addition, it has been shown that oxaliplatin remains highly
cytotoxic in cells that overexpress TS. In breast cancer-derived
cell line with tetracycline-regulated expression of TS, TS over-
expression confers an increased resistance to TS-targeted drugs,
while the growth inhibitory effect of other drugs such as
oxaliplatin is unaffected by TS upregulation (Longley et al,
2001). The use of an oxaliplatin-containing chemotherapy in our
study could explain our findings. Furthermore, the absence of TS
effect on RT treatment makes our hypothesis sound.
When we explored the potential predictive value of other
molecular markers, we found no effect on response. Contrary to a
previous study on rectal cancer patients receiving preoperative RT,
showing that VEGF expression in NR was significantly greater than
in completely responsive tumours, the present study does not
demonstrate a significant role of VEGF overexpression on clinical
response (Zlobec et al, 2005a). Also, the present data do not
confirm the previously reported value of high microsatellite
instability, p21WAF1/C1PI and p53 for predicting tumour
response to preoperative RT or RCT (Charara et al, 2004; Kelley
et al, 2005; Komuro et al, 2005). These conflicting results may be
attributable to the retrospective nature and the limited detection
power inherent in studies that test small subsets of patients.
An interesting finding, although not directly related to the goal
of this work, was the observation that lymph node status was
significantly associated with tumour response. Lymph node status
was first demonstrated to have prognostic value in patients with
locally advanced rectal cancer treated on the CAO/ARO/AIO-94
trial of the German Rectal Cancer Study Group (Liersch et al,
2006). All patients who developed cancer recurrence had a
persistently positive lymph node status after therapy, which
reflects the poor prognosis of these patients. In our study, lymph
node status turned out to be the most important predictive factor,
with a significantly higher response rate in N0 tumours as
compared with N1–2 tumours (47 vs 9%; P¼0.004), indepen-
dently of treatment and TS status.
In conclusion, despite the small sample size and the retro-
spective nature of the study, our data indicate that lymph
node status is the most important predictive marker of tumour
response to preoperative treatment in rectal cancer. In addition,
among a variety of biological markers evaluated, immunohisto-
chemical assessment of TS from pretreatment tumour biopsies was
the only one with potential for the prediction of tumour response
to preoperative oxaliplatin-based RCT. This observation may
deserve further validation in prospective studies of FOLFOX-RT
regimens.
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